MGRX
Mangoceuticals, Inc.
Medical - Healthcare Information Services
Market Cap$6M
5Y Perf.-97.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MGRX vs PFE
Revenue, margins, valuation, and 5-year total return — side by side.
PFE
Pfizer Inc.
Drug Manufacturers - General
Market Cap$150.77B
5Y Perf.-35.0%
MGRX vs PFE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MGRX | PFE |
|---|---|---|
| Industry | Medical - Healthcare Information Services | Drug Manufacturers - General |
| Market Cap | $6M | $150.77B |
| Revenue (TTM) | $467K | $63.31B |
| Net Income (TTM) | $-20M | $7.49B |
| Gross Margin | 60.6% | 69.3% |
| Operating Margin | -41.4% | 23.4% |
| Forward P/E | — | 9.0x |
| Total Debt | $215K | $67.42B |
| Cash & Equiv. | $59K | $1.14B |
MGRX vs PFE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MGRX
PFE
| Stock | Mar 23 | May 26 | Return |
|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | 100 | 2.1 | -97.9% |
| Pfizer Inc. (PFE) | 100 | 65.0 | -35.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MGRX vs PFE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PFE leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Mangoceuticals, Inc. is the stronger pick specifically for dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
MGRX
Mangoceuticals, Inc.
The Income Pick
MGRX is the clearest fit if your priority is dividends.
- 100.0% yield, 1-year raise streak, vs PFE's 6.5%
Best for: dividends
PFE
Pfizer Inc.
The Income Pick
PFE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 15 yrs, beta 0.54, yield 6.5%
- Rev growth -1.6%, EPS growth -3.5%, 3Y rev CAGR -14.6%
- 30.7% 10Y total return vs MGRX's -99.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PFE | -1.6% revenue growth vs MGRX's -15.8% |
| Quality / Margins | PFE | 11.8% margin vs MGRX's -42.5% |
| Stability / Safety | PFE | Beta 0.54 vs MGRX's 0.90 |
| Dividends | MGRX | 100.0% yield, 1-year raise streak, vs PFE's 6.5% |
| Momentum (1Y) | PFE | +23.4% vs MGRX's -80.3% |
| Efficiency (ROA) | PFE | 3.6% ROA vs MGRX's -106.4%, ROIC 7.5% vs -83.8% |
MGRX vs PFE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MGRX vs PFE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPFELAGGINGMGRX
MGRXMangoceuticals, Inc.
1leads
PFEPfizer Inc.
4leads
6 Total Categories
CATEGORYLEADERvs MGRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PFE5/6
Valuation MetricsMultiples, price ratios, and targets
MGRX2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PFE6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PFE6/6
Risk & VolatilityBeta, volatility, and downside exposure
PFE2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
PFE leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PFE is the larger business by revenue, generating $63.3B annually — 135604.9x MGRX's $466,908. PFE is the more profitable business, keeping 11.8% of every revenue dollar as net income compared to MGRX's -42.5%. On growth, PFE holds the edge at +5.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| RevenueTrailing 12 months | $466,908 | $63.3B |
| EBITDAEarnings before interest/tax | -$17M | $21.0B |
| Net IncomeAfter-tax profit | -$20M | $7.5B |
| Free Cash FlowCash after capex | -$6M | $9.5B |
| Gross MarginGross profit ÷ Revenue | +60.6% | +69.3% |
| Operating MarginEBIT ÷ Revenue | -41.4% | +23.4% |
| Net MarginNet income ÷ Revenue | -42.5% | +11.8% |
| FCF MarginFCF ÷ Revenue | -12.6% | +15.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -36.8% | +5.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +30.5% | -9.5% |
PFE leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
MGRX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| Market CapShares × price | $6M | $150.8B |
| Enterprise ValueMkt cap + debt − cash | $6M | $217.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.08x | 19.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.95x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 10.67x |
| Price / SalesMarket cap ÷ Revenue | 9.28x | 2.41x |
| Price / BookPrice ÷ Book value/share | 0.05x | 1.74x |
| Price / FCFMarket cap ÷ FCF | — | 16.61x |
MGRX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
PFE leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
PFE delivers a 8.3% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-115 for MGRX. MGRX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PFE's 0.78x. On the Piotroski fundamental quality scale (0–9), PFE scores 7/9 vs MGRX's 4/9, reflecting strong financial health.
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -114.6% | +8.3% |
| ROA (TTM)Return on assets | -106.4% | +3.6% |
| ROICReturn on invested capital | -83.8% | +7.5% |
| ROCEReturn on capital employed | -107.8% | +9.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 0.78x |
| Net DebtTotal debt minus cash | $156,309 | $66.3B |
| Cash & Equiv.Liquid assets | $58,653 | $1.1B |
| Total DebtShort + long-term debt | $214,962 | $67.4B |
| Interest CoverageEBIT ÷ Interest expense | -581.90x | 4.02x |
PFE leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PFE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PFE five years ago would be worth $8,866 today (with dividends reinvested), compared to $59 for MGRX. Over the past 12 months, PFE leads with a +23.4% total return vs MGRX's -80.3%. The 3-year compound annual growth rate (CAGR) favors PFE at -6.5% vs MGRX's -73.1% — a key indicator of consistent wealth creation.
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -58.9% | +7.0% |
| 1-Year ReturnPast 12 months | -80.3% | +23.4% |
| 3-Year ReturnCumulative with dividends | -98.0% | -18.4% |
| 5-Year ReturnCumulative with dividends | -99.4% | -11.3% |
| 10-Year ReturnCumulative with dividends | -99.4% | +30.7% |
| CAGR (3Y)Annualised 3-year return | -73.1% | -6.5% |
PFE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
PFE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PFE is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than MGRX's 0.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PFE currently trades 92.2% from its 52-week high vs MGRX's 12.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 0.54x |
| 52-Week HighHighest price in past year | $2.75 | $28.75 |
| 52-Week LowLowest price in past year | $0.27 | $21.97 |
| % of 52W HighCurrent price vs 52-week peak | +12.8% | +92.2% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 43.2 |
| Avg Volume (50D)Average daily shares traded | 7.4M | 33.2M |
PFE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — MGRX and PFE each lead in 1 of 2 comparable metrics.
Analyst Outlook
For income investors, MGRX offers the higher dividend yield at 100.00% vs PFE's 6.48%.
| Metric | MGRXMangoceuticals, I… | PFEPfizer Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $27.27 |
| # AnalystsCovering analysts | — | 39 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | +6.5% |
| Dividend StreakConsecutive years of raises | 1 | 15 |
| Dividend / ShareAnnual DPS | $0.41 | $1.72 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Evenly matched — MGRX and PFE each lead in 1 of 2 comparable metrics.
Key Takeaway
PFE leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MGRX leads in 1 (Valuation Metrics). 1 tied.
Best OverallPfizer Inc. (PFE)Leads 4 of 6 categories
Loading custom metrics...
MGRX vs PFE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MGRX or PFE a better buy right now?
For growth investors, Pfizer Inc.
(PFE) is the stronger pick with -1. 6% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Pfizer Inc. (PFE) a "Hold" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MGRX or PFE?
Over the past 5 years, Pfizer Inc.
(PFE) delivered a total return of -11. 3%, compared to -99. 4% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: PFE returned +30. 7% versus MGRX's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MGRX or PFE?
By beta (market sensitivity over 5 years), Pfizer Inc.
(PFE) is the lower-risk stock at 0. 54β versus Mangoceuticals, Inc. 's 0. 90β — meaning MGRX is approximately 66% more volatile than PFE relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MGRX or PFE?
By revenue growth (latest reported year), Pfizer Inc.
(PFE) is pulling ahead at -1. 6% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: Mangoceuticals, Inc. grew EPS 48. 7% year-over-year, compared to -3. 5% for Pfizer Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MGRX or PFE?
Pfizer Inc.
(PFE) is the more profitable company, earning 12. 4% net margin versus -1413. 6% for Mangoceuticals, Inc. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus -1294. 4% for MGRX. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MGRX or PFE?
All stocks in this comparison pay dividends.
Mangoceuticals, Inc. (MGRX) offers the highest yield at 100. 0%, versus 6. 5% for Pfizer Inc. (PFE).
07Is MGRX or PFE better for a retirement portfolio?
For long-horizon retirement investors, Pfizer Inc.
(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Both have compounded well over 10 years (PFE: +30. 7%, MGRX: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MGRX and PFE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(MGRX: -36.8% · PFE: 5.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.